The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s CRISPR Gene Editing Global Market Report 2023, the CRISPR gene editing market is expected to show promising growth in the forecast period.

Market Overview

• Current Size: The CRISPR gene editing market will expand from $1.78 billion in 2023 to $2.26 billion in 2024, with a CAGR of 26.9%.
• Future Projections: Expected to reach $5.92 billion by 2028, growing at a CAGR of 27.2%.

Historical Growth Drivers

• Demand for Genome Editing: Increased interest in CRISPR technology for its precision and effectiveness in gene editing.
• Government Funding: Rising investments in research and development of gene editing technologies.
• Cancer and Chronic Diseases: Higher cancer cases and chronic diseases have driven demand for advanced treatments.
• Awareness and Infrastructure: Greater awareness about CRISPR and improved healthcare infrastructure have supported market growth.

View More On The CRISPR Gene Editing Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Future Growth Drivers

• Genetic Disorders: Growing prevalence of genetic disorders is boosting the need for CRISPR applications.
• Precision Medicine: Emphasis on personalized medicine drives the adoption of CRISPR technologies.
• Investment in R&D: Increased funding in CRISPR research and development fuels innovation.
• Aging Population: Rising geriatric population contributes to higher demand for genetic therapies.

Genetic Disorder Prevalence Fuels Market Growth

• Genetic Disorders: Conditions like cystic fibrosis and sickle cell anemia benefit from CRISPR’s precision.
• Prevalence Statistics: Approximately 6,000 babies born annually in the US have Down syndrome, highlighting the need for advanced genetic treatments.

Major Market Players

• Key Companies: Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, GenScript, and others are leading the market.
• Innovations: These companies are developing cutting-edge CRISPR tools to enhance gene editing precision and efficiency.

Innovations in CRISPR Gene Editing

• New Tools: Innovations like QIAGEN’s QIAprep& CRISPR Kit and CRISPR Q-Primer streamline gene editing processes.
  • Example: QIAGEN’s tools reduce experiment time by seven days through integrated sample preparation and detection.

Strategic Collaborations

• Pfizer and Beam Therapeutics: In January 2022, Pfizer partnered with Beam Therapeutics to develop treatments for rare genetic diseases affecting the liver, muscles, and central nervous system.
• Collaboration Goals: Focus on advancing CRISPR gene editing technologies for targeted therapies.

Market Segmentation

• By Type: CRISPR-Associated Nuclease (Cas Nuclease), Guide RNA, DNA Ligase, Restriction Endonuclease, Other Types.
• By Services: Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products, Other Services.
• By Technology: CRISPR/Cas9, Zinc Finger Nucleases, Other Technologies.
• By Application: Agricultural, Biomedical, Industrial, Genome Engineering, Disease Models, Functional Genomics, Other Applications.
• By End User: Academic Institutes, Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical and Biopharmaceutical Companies.

Regional Insights

• North America: The largest market in 2023, with continued dominance expected.
• Asia-Pacific: Expected to be the fastest-growing region in the forecast period.

The CRISPR gene editing market is on a rapid growth trajectory, driven by advances in technology, rising genetic disorder prevalence, and significant investments in research and development. The increasing emphasis on precision medicine and innovations in gene editing tools are expected to further propel market expansion.

Request A Sample Of The Global CRISPR Gene Editing Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15549&type=smp